PITCH SPEAKERS

Dr. Mika Mizunuma, COO of Craif, drives global operations, scaling, and execution across teams. With experience in pharma R&D, consulting, and digital health, she advances Craif’s growth and efficiency. Previously at AstraZeneca, she led medical launch strategies, then at McKinsey advised pharma and medtech clients. In 2017, she founded a digital health startup providing AI-driven patient engagement solutions. She holds a Ph.D. in Pharmaceutical Sciences from the University of Tokyo and a bachelor’s degree from Kyoto University.

Craif is a company aiming to shift the focus of medicine from ""treatment"" to ""prevention and early detection"" by leveraging the power of biotechnology and AI, thereby realizing the early detection of diseases such, as cancer, and personalized medicine. 【Product】 We have developed and offer ""MySignaL-Scan,"" a urine cancer test that enables the early detection of cancer risk at an asymptomatic stage. This test focuses on ""microRNA,"" which plays a vital role in cancer onset and progression, and utilizes ""Bio-AI"" to detect cancer-specific signals with AI technology. We are also advancing the development of a Bio-AI-based medical device in both Japan and the United States as a new option to support the early detection and proper diagnosis of pancreatic cancer. 【Our Science】 We are dedicated to developing next-generation testing and medical devices that enable the early detection of diseases, including cancer, and facilitate optimal treatment for each individual. This is achieved through ""Bio-AI,"" which integrates our proprietary biomarker analysis platform, NANO IP®︎ (NANO Intelligence Platform®︎)—which analyzes diverse biosignals emitted by living organisms, such as DNA and RNA present in bodily fluids like urine—with state-of-the-art AI algorithms.